Clinical trial NCT02871050: Castleman Disease Collaborative Network Biobank
Official title: The Castleman Disease Collaborative Network Biobank: A Collection of Biospecimens and Clinical Data to Facilitate Research
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Castleman Disease
Castleman's Disease
Giant Lymph Node Hyperplasia
Angiofollicular Lymph Hyperplasia
Angiofollicular Lymph Node Hyperplasia
Angiofollicular Lymphoid Hyperplasia
GLNH
Hyperplasia
Giant Lymph Node
Keywords: Biobank
biorepository
Castlebank
Castleman Disease
CD
MCD
iMCD
Castleman
Castleman's Disease
multicentric Castleman's disease
multicentric Castleman disease
Angiofollicular Lymph Hyperplasia
Lead sponsor: Castleman Disease Collaborative Network
Sponsor class: OTHER
First posted: 2016-08-18
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Castleman Disease patients worldwide

Brief summary: The purpose of this study is to create a biobank, which collects, stores, and distributes samples of human tissues, blood, and related health information to qualified scientists, in order to help doctors and researchers better understand why Castleman Disease occurs and develop ways to better treat and prevent it.

Detailed description: The CDCN proposes to establish a biobank and associated clinical data for Castleman disease. Tissue and fluid (blood and saliva) samples will be collected both prospectively and retrospectively. Blood or saliva samples may also be collected from relatives of Castleman patients. Because of the scarcity of these samples, it will be necessary to make efforts to access all available cases. Many cases will occur at hospitals that do not have an existing relationship with the CDCN and may not have experience with tissue procurement; however, this is the only way to obtain the vast majority of samples. Samples may be used immediately, banked for future use, or further processed into DNA, cell lines, tissue microarrays, etc.

The samples will be stored at Precision for Medicine, a biorepository company that specializes in collection, processing, storage and distribution of biospecimens. Only researchers (US or international) who have applied to the CDCN and have been approved by the Biobank Advisory Board will be eligible to access biospecimens and/or data. The Biobank Advisory Board will be comprised of clinicians and scientists with experience in clinical and investigational practices in Castleman Disease.

Eligibility criteria: Inclusion Criteria

* Potential study participants may be of any age, gender, or ethnicity who have been diagnosed with Castleman disease

Exclusion Criteria

* None

Primary outcomes:
measure: Samples Collected
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Castleman Disease Collaborative Network
state: Pennsylvania
Study officials:
affiliation: Executive Director of Castleman Disease Collaborative Network
name: David C Fajgenbaum, MD, MBA, MSc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, Krymskaya VP, Kelleher D, Rubenstein AH, Fajgenbaum DC. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol. 2016 Apr;3(4):e163-75. doi: 10.1016/S2352-3026(16)00006-5. Epub 2016 Mar 17.
citation: Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood. 2014 May 8;123(19):2924-33. doi: 10.1182/blood-2013-12-545087. Epub 2014 Mar 12.